# Peritumoral and Periganglionic Infiltration of Levobupivacaine Prior to Conservative Surgery for Triple-negative Breast Cancer

> **NCT07458204** · PHASE2 · NOT_YET_RECRUITING · sponsor: **Institut Jean-Godinot** · enrollment: 760 (estimated)

## Conditions studied

- Triple-negative Breast Cancer

## Interventions

- **DRUG:** LVB infiltration

## Key facts

- **NCT ID:** NCT07458204
- **Lead sponsor:** Institut Jean-Godinot
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** NOT_YET_RECRUITING
- **Start date:** 2026-10-01
- **Primary completion:** 2031-10-01
- **Final completion:** 2032-10-01
- **Target enrollment:** 760 (ESTIMATED)
- **Last updated:** 2026-03-09


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT07458204

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT07458204, "Peritumoral and Periganglionic Infiltration of Levobupivacaine Prior to Conservative Surgery for Triple-negative Breast Cancer". Retrieved via AI Analytics 2026-05-26 from https://api.ai-analytics.org/clinical/NCT07458204. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*